Published on February 9, 2010 at 1:08 AM
Emerging Healthcare Solutions, Inc. (Pinksheets:EHSI) announced today that management has formally delivered an actionable Term Sheet to ThromboVision for review and that follow up communications have been very favorable. The Term Sheet review is a major positive step that is necessary to pursue final terms under EHSI’s recent option agreement with ThromboVision, a company that has licensed the patent on the revolutionary new T-Guide® Platelet Function Analyzer, which is currently going through regulatory clearance review.
The T-Guide® is a brilliant development of new technology that does not require direct handling of blood, provides an economical testing means and should enable doctors to directly measure platelet status as easily as measuring cholesterol. The T-Guide® analyzer is a desktop instrument that uses a disposable test kit. The unit is designed so it can be located at doctor’s offices and could become a front line technology that could help prevent heart attacks, strokes and stent occlusions by directly analyzing a patient’s platelet status at the physician’s office. In the US, physicians incur 80 million cardiovascular visits each year, with over 30 million of these patients utilizing Aspirin or Plavix® platelet therapy.
The emerging healthcare industry is expected to continue strong expansion, regardless of what will eventually result in Washington, which could be beneficial to many cutting-edge companies such as Enzo Biochem (NYSE: ENZ), National Dentex (NASDAQ: NADX), Inverness Medical Innovations. (NYSE: IMA) and Radnet Inc. (NASDAQ: RDNT).
Source: Emerging Healthcare Solutions, Inc.